نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :Cells 2021

Liver metastases are a major management problem; since they occur in tumors of different origin, often multiple, difficult to visualize and can lie dormant for many years. Patients with liver usually die their disease, mostly due failure, systemic treatments unable eradicate micro-metastasis, interventional loco-regional procedures cannot treat all existing ones. Cholangiocarcinoma (CCA) is the...

Journal: : 2023

In case of locally advanced soft tissue sarcomas the extremities (STS), large size which does not allow resection with preservation limb, isolated regional perfusion (IRP) limb is considered as one effective treatment options. Aim. To evaluate long-term outcomes IRP melphalan under conditions hyperthermia for STS extremities. Materials and methods. We conducted a prospective cohort clinical stu...

Journal: :Neuro-oncology 2023

Abstract Choroid plexus carcinoma is a very rare pediatric tumor located in the fourth and lateral ventricles of brain. It known to have severe clinical history significant side effects because intensive noxious chemotherapies. Due disease’s rarity scarcity biologically relevant substrates, advance new therapeutical techniques for this condition has been exceedingly constrained. A human patient...

Journal: :Blood 2002
Philippe Moreau Thierry Facon Michel Attal Cyrille Hulin Mauricette Michallet Frédéric Maloisel Jean-Jacques Sotto François Guilhot Gérald Marit Chantal Doyen Jérôme Jaubert Jean-Gabriel Fuzibet Sylvie François Lotfi Benboubker Matthieu Monconduit Laurent Voillat Margaret Macro Christian Berthou Véronique Dorvaux Bernard Pignon Bernard Rio Thomas Matthes Philippe Casassus Denis Caillot Norbert Najman Bernard Grosbois Régis Bataille Jean-Luc Harousseau

High-dose therapy has become a common treatment for myeloma. The objective of this study (Intergroupe Francophone du Myélome [IFM] 9502 trial) was to compare in a prospective and randomized trial the 2 most widely used conditioning regimens before autologous stem cell transplantation in newly diagnosed symptomatic patients younger than 65 years old: 8 Gy total body irradiation plus 140 mg/m(2) ...

Journal: :Blood 1990
B Barlogie S Jagannath D O Dixon B Cheson L Smallwood A Hendrickson J D Purvis E Bonnem R Alexanian

High-dose melphalan has induced remissions in about 40% of patients with refractory myeloma, but the mortality has been high, at about 20%, due to complications of prolonged granulocytopenia. In an attempt to stimulate earlier granulocyte recovery, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) was administered subcutaneously to 23 patients with refractory myeloma w...

Journal: :Haematologica 2006
Vittorio Perfetti Salvatore Siena Giovanni Palladini Marco Bregni Massimo Di Nicola Laura Obici Michele Magni Laura Brunetti Alessandro Massimo Gianni Giampaolo Merlini

BACKGROUND AND OBJECTIVES High-dose melphalan with autologous peripheral blood stem cell transplantation (ASCT) is an effective treatment for systemic primary amyloidosis. This procedure is, however, associated with substantial toxicity and mortality, particularly if the heart is involved. Refined selection of patients suitable for transplantation and personalized adaptation of the doses of mel...

Journal: :Haematologica 2014
Monika Engelhardt Evangelos Terpos Martina Kleber Francesca Gay Ralph Wäsch Gareth Morgan Michele Cavo Niels van de Donk Andreas Beilhack Benedetto Bruno Hans Erik Johnsen Roman Hajek Christoph Driessen Heinz Ludwig Meral Beksac Mario Boccadoro Christian Straka Sara Brighen Martin Gramatzki Alessandra Larocca Henk Lokhorst Valeria Magarotto Fortunato Morabito Meletios A Dimopoulos Hermann Einsele Pieter Sonneveld Antonio Palumbo

Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo ...

Journal: :Environmental Health Perspectives 1995
I. C. M. MacLennan J. Cusick

In the Medical Research Council's lVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first l...

2010
Se Ryeon Lee Seok Jin Kim Yong Park Hwa Jung Sung Chul Won Choi Byung Soo Kim

BACKGROUND High-dose melphalan (200 mg/m(2)) with autologous stem cell transplantation (ASCT) is the standard treatment for young patients with multiple myeloma (MM). However, the response rates after ASCT are often unsatisfactory. We performed a pilot study by using bortezomib-melphalan as conditioning regimen for ASCT in Korean patients with MM. METHODS The conditioning regimen consisted of...

Journal: :European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2005
Sander Romijn Jeroen M H Hendriks Bart P Van Putte Joost Weyler Gunther Guetens Gert De Boeck G Ernst A De Bruijn Paul E Y Van Schil

OBJECTIVE Isolated lung perfusion (ILuP) is an experimental technique currently tested to increase the 5-year survival of 40% after surgical resection of pulmonary metastases from certain solid tumors. The standard technique of anterograde perfusion was compared with retrograde isolated lung perfusion in which the drug is introduced through the pulmonary veins while the effluent is collected fr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید